[go: up one dir, main page]

TR200000374T2 - Akut akciğer harabiyeti ve fibrozitinin alfavbeta6 antagonistleriyle tedavisi. - Google Patents

Akut akciğer harabiyeti ve fibrozitinin alfavbeta6 antagonistleriyle tedavisi.

Info

Publication number
TR200000374T2
TR200000374T2 TR2000/00374T TR200000374T TR200000374T2 TR 200000374 T2 TR200000374 T2 TR 200000374T2 TR 2000/00374 T TR2000/00374 T TR 2000/00374T TR 200000374 T TR200000374 T TR 200000374T TR 200000374 T2 TR200000374 T2 TR 200000374T2
Authority
TR
Turkey
Prior art keywords
fibrosis
antagonists
treatment
alfavbeta6
acute lung
Prior art date
Application number
TR2000/00374T
Other languages
English (en)
Inventor
Huang Xiaozhu
Sheppard Dean
Pytela Robert
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of TR200000374T2 publication Critical patent/TR200000374T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Akut akciger harabiyeti ve fibrozitinin tedavisi için HL47412 ve HL53949 antagonistlerini içeren terkipler ve yöntem.
TR2000/00374T 1997-08-08 1998-08-07 Akut akciğer harabiyeti ve fibrozitinin alfavbeta6 antagonistleriyle tedavisi. TR200000374T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5506097P 1997-08-08 1997-08-08

Publications (1)

Publication Number Publication Date
TR200000374T2 true TR200000374T2 (tr) 2000-09-21

Family

ID=21995323

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2002/02323T TR200202323T2 (tr) 1997-08-08 1998-08-07 Akut akciğer harabiyeti ve fibrozitinin alfavß6 antagonistleriyle tedavisi
TR2000/00374T TR200000374T2 (tr) 1997-08-08 1998-08-07 Akut akciğer harabiyeti ve fibrozitinin alfavbeta6 antagonistleriyle tedavisi.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2002/02323T TR200202323T2 (tr) 1997-08-08 1998-08-07 Akut akciğer harabiyeti ve fibrozitinin alfavß6 antagonistleriyle tedavisi

Country Status (23)

Country Link
US (5) US20020004482A1 (tr)
EP (3) EP1504764B1 (tr)
JP (2) JP2001513333A (tr)
KR (1) KR100586202B1 (tr)
CN (1) CN1267224A (tr)
AT (3) ATE511850T1 (tr)
AU (1) AU739283B2 (tr)
BR (1) BR9814040A (tr)
CA (1) CA2297736A1 (tr)
CY (2) CY1110462T1 (tr)
CZ (1) CZ299768B6 (tr)
DE (2) DE69840113D1 (tr)
DK (2) DK1930022T3 (tr)
EE (1) EE04752B1 (tr)
ES (3) ES2235350T3 (tr)
HU (1) HU228900B1 (tr)
IL (2) IL134288A0 (tr)
NZ (2) NZ515955A (tr)
PL (2) PL201716B1 (tr)
PT (3) PT1930022E (tr)
RU (1) RU2221589C2 (tr)
TR (2) TR200202323T2 (tr)
WO (1) WO1999007405A1 (tr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962643A (en) * 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
IL134288A0 (en) * 1997-08-08 2001-04-30 Univ California TREATMENT OF ACUTE LUNG INJURY AND FIBROSIS WITH ANTAGONISTS OF ανβ6
KR100746522B1 (ko) * 1999-04-22 2007-08-07 바이오겐 아이덱 엠에이 인코포레이티드 인테그린 알파-4 서브유닛의 길항 물질을 사용하는섬유증의 치료 방법
DE19929410A1 (de) * 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
AUPR230500A0 (en) * 2000-12-22 2001-01-25 University Of Newcastle Research Associates Limited, The A method of modulating map kinase mediated cellular activity and agents useful in same
ATE409047T1 (de) * 2001-04-30 2008-10-15 Lilly Co Eli Humanisierte antikörper
CN102659946A (zh) * 2002-03-13 2012-09-12 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
EP1492870A4 (en) * 2002-04-12 2005-08-03 Raven Biotechnologies Inc ANTIBODIES BINDING TO INTEGRIN-ALPHA-V-BETA-6 AND METHOD OF USE THEREOF
EP2394662B1 (en) 2004-04-02 2018-03-21 The Regents of The University of California Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
JP2009542810A (ja) 2006-07-10 2009-12-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｍａｄ４欠損癌の増殖を阻害するための組成物および方法
TW200815474A (en) 2006-08-03 2008-04-01 Astrazeneca Ab Antibodies alphaVbeta6 and uses thereof
JP2010506944A (ja) * 2006-10-19 2010-03-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア インテグリンαＶβ６のアンタゴニストを用いる慢性喘息の処置および予防
EP2543389A3 (en) 2007-08-02 2013-04-24 Gilead Biologics, Inc. Methods and compositions inhibiting a lysyl oxidase (-like) protein for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
KR101046317B1 (ko) * 2008-07-04 2011-07-05 이종대 조력발전 방법 및 그 장치
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
CA2767409C (en) 2009-07-24 2018-10-30 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin
RU2015124151A (ru) * 2009-08-21 2015-12-27 Джилид Байолоджикс, Инк. Способы и композиции для лечения фиброзных заболеваний легких
RU2012110585A (ru) 2009-08-21 2013-09-27 Джилид Байолоджикс, Инк. Каталичические домены лизилоксидазы и loxl2
RU2549684C2 (ru) * 2010-02-04 2015-04-27 Джилид Байолоджикс, Инк. Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
EA031069B1 (ru) 2012-02-17 2018-11-30 Сиэтл Дженетикс, Инк. АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αVβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
EP2784511A1 (en) 2013-03-27 2014-10-01 Universität Zürich Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma
JP6104312B2 (ja) * 2014-06-19 2017-03-29 日東電工株式会社 組織再生促進剤
US20190144547A1 (en) * 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
WO2019040608A1 (en) 2017-08-22 2019-02-28 Biogen Ma Inc. PHARMACEUTICAL COMPOSITIONS AND DOSAGE SCHEMES CONTAINING ANTI-ALPHA (V) BETA ANTIBODIES (6)
MX2022006132A (es) 2019-12-05 2022-06-17 Seagen Inc Anticuerpos anti alfa-v beta-6 (avb6) y conjugados de anticuerpo-farmaco.
CN115989235A (zh) * 2020-05-07 2023-04-18 普利安特治疗公司 使用氨基酸化合物治疗呼吸系统疾病的方法
CN120960406A (zh) * 2024-05-16 2025-11-18 浙江大学 靶向整合素αVβ6的CAR-免疫细胞在预防和/或治疗纤维化疾病中的应用
WO2026012032A1 (en) * 2024-07-10 2026-01-15 Wuxi Biologics (Shanghai) Co., Ltd. Antibodies against integrin and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5654270A (en) * 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
ES2084688T3 (es) 1988-12-20 1996-05-16 Jolla Cancer Res Found Conjugados de polipeptido-polimero para el tratamiento de heridas.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5962643A (en) 1991-07-11 1999-10-05 The Regents Of The University Of California Integrin β subunit and uses thereof
TW352384B (en) * 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
US5770565A (en) * 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
PT719859E (pt) * 1994-12-20 2003-11-28 Merck Patent Gmbh Anticorpo monoclonal anti-alfa v-integrina
IL134288A0 (en) * 1997-08-08 2001-04-30 Univ California TREATMENT OF ACUTE LUNG INJURY AND FIBROSIS WITH ANTAGONISTS OF ανβ6

Also Published As

Publication number Publication date
HUP0003547A3 (en) 2002-05-28
HUP0003547A2 (hu) 2001-02-28
US20020004482A1 (en) 2002-01-10
TR200202323T2 (tr) 2002-12-23
AU8774398A (en) 1999-03-01
PT1930022E (pt) 2011-08-01
EP0996460B1 (en) 2005-01-12
NZ502546A (en) 2002-02-01
CN1267224A (zh) 2000-09-20
US20040208878A1 (en) 2004-10-21
PL201716B1 (pl) 2009-05-29
EE04752B1 (et) 2006-12-15
PT996460E (pt) 2005-04-29
EP1930022B1 (en) 2011-06-08
US7544358B2 (en) 2009-06-09
AU739283B2 (en) 2001-10-11
PL199014B1 (pl) 2008-08-29
CY1111792T1 (el) 2015-10-07
US6692741B2 (en) 2004-02-17
CY1110462T1 (el) 2015-04-29
CZ2000413A3 (cs) 2000-11-15
EP0996460A1 (en) 2000-05-03
DE69828614T2 (de) 2006-02-09
DE69828614D1 (de) 2005-02-17
EP1504764A1 (en) 2005-02-09
US20010056076A1 (en) 2001-12-27
HU228900B1 (en) 2013-06-28
ATE286742T1 (de) 2005-01-15
DK1504764T3 (da) 2008-11-17
EP0996460A4 (en) 2001-03-07
JP2009001587A (ja) 2009-01-08
ES2311131T3 (es) 2009-02-01
EP1504764B1 (en) 2008-10-08
IL134288A0 (en) 2001-04-30
PT1504764E (pt) 2009-01-14
NZ515955A (en) 2003-04-29
JP2001513333A (ja) 2001-09-04
DK1930022T3 (da) 2011-07-25
ES2364703T3 (es) 2011-09-12
KR100586202B1 (ko) 2006-06-07
PL341029A1 (en) 2001-03-26
DE69840113D1 (de) 2008-11-20
CA2297736A1 (en) 1999-02-18
US7150871B2 (en) 2006-12-19
ATE511850T1 (de) 2011-06-15
KR20010022740A (ko) 2001-03-26
IL134288A (en) 2008-07-08
EE200000068A (et) 2000-10-16
WO1999007405A1 (en) 1999-02-18
US6316601B1 (en) 2001-11-13
EP1930022A1 (en) 2008-06-11
BR9814040A (pt) 2000-10-03
CZ299768B6 (cs) 2008-11-19
ATE410179T1 (de) 2008-10-15
ES2235350T3 (es) 2005-07-01
US20070148173A1 (en) 2007-06-28
RU2221589C2 (ru) 2004-01-20

Similar Documents

Publication Publication Date Title
TR200000374T2 (tr) Akut akciğer harabiyeti ve fibrozitinin alfavbeta6 antagonistleriyle tedavisi.
EA199800667A1 (ru) Новые фенантридины
ID24331A (id) Komposisi dan metode untuk memperlakukan tanaman dengan bahan-bahan kimia eksogen
FI971969A0 (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
DE69832158D1 (de) Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
NO20003096D0 (no) Sammensetninger og fremgangsmÕter for behandling av ADD
ID28846A (id) 2-fenilbenzimidazol dan 2_fenilindol, pembuatan dan penggunaanya
PL316658A1 (en) Novel application of serotonin antagonists
ZA973503B (en) Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents.
BR9711420A (pt) Injetor sem agulha
FI971750A0 (fi) Koostumuksia multippeliskleroosia varten ja sen hoito
IT1294080B1 (it) Procedimento ed apparato per l'ispezione esterna di contenitori.
FI964342A7 (fi) Halogeenimetyyliamideja IL-1beta-proteaasi-inhibiittoreina
BG100248A (bg) Инхибитори на скваленсинтетаза
FI963394A7 (fi) Yskää vastustava koostumus, joka sisältää yskää vastustavaa ainetta ja bentsydamiinia
PT811593E (pt) Agentes insecticidas e acaricidas 1,4-diaril-2-fluor-2-buteno
ITRM950085A0 (it) Composizione stagionabili di amine.
IT1290923B1 (it) Sacchetto e metodo per la produzione dello stesso.
NL1007839A1 (nl) Formulering en gebruik.
HUP0102995A3 (en) Agents and method for the protective treatment of wood
ITBO930519A0 (it) Metodo e macchina per la realizzazione di sigarette ventilate.
ITBZ950045A0 (it) Gioiello e procedimento per la realizzazione dello stesso.
EE04494B1 (et) 1-oksa-, asa- ja tianaftaleen-2-oon biseetrid fosfolambaani inhibiitoritena
NO985558D0 (no) Ny forbedret formulering for behandling av tromboembolisme